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Molecular genetics of cystinuria in French Canadians: Identification of
four novel mutations in Type I patients. Cystinuria, a hereditary disorder
of cystine and dibasic amino acid reabsorption, has been classified into
three subtypes on the basis of urinary excretion in obligate heterozygous
parents. Thirteen cystinuric patients, identified primarily through the
Quebec newborn urinary screening program, were investigated by pheno-
typic classification and by mutational analysis of the D2H (rBAT) gene.
Mutations were identified on 7 of 25 alleles; all of these 7 mutant alleles
were associated with Type I cystinuria. Four of the mutations (a large
deletion, a 5'splice site mutation, a 2 bp deletion, and a nonsense
mutation) have not been previously reported. These findings suggest that
abnormalities in the D2H gene may account for only one subtype (Type I)
of cystinuria, and that this subtype can be caused by a wide variety of
population-specific mutations.
Cystinuria is an autosomal recessive disorder of the kidneys and
small intestine, affecting a luminal transport mechanism shared by
cystine and the dibasic amino acids: ornithine, arginine and lysine.
The incidence of cystinuria in Quebec is 1/7000 [1]; worldwide
incidence varies considerably, from 1/2500 in Jews of Libyan
origin to 1/15,000 in the United States 121.
In 1993, a human eDNA (D2H or rBAT) was isolated, which
induced cystine transport in Xenopus oocytes; the Genome Data
Base nomenclature for this gene is SLC3A1. The gene was
mapped by somatic cell hybridization to chromosome 2 [3] and we
used fluorescence in situ hybridization for mapping it to subregion
2p2l [4], the same region that had been suggested to contain the
cystinuria gene by linkage analysis [5]. The identification of D2H
mutations in Italian and Spanish patients [6, 71 and in Middle
Eastern and American patients [8] has confirmed that the D2H
gene is associated with at least one form of cystinuria. The exact
role of its gene product, however, remains to be defined, since
structural analyses have suggested that D2H may encode an
activator or one component of the luminal transporter [9]. The
genomic structure for D2H has not been reported.
Three distinct phenotypes for cystinuria have been described,
based on urinary excretion in obligate heterozygotes: Type I
(silent carriers); Type II (moderate elevation); and Type III (mild
elevation) [2]. Earlier studies had suggested that the distinct
phenotypes were due to allelic variation at a single locus [2].
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However, in a prospective analysis, we found that Type I/Ill
compounds excreted less cystine than Type I/I probands [10]. This
observation was unexpected since the Type 111/N heterozygotes
excrete higher levels of cystine than their Type I/N counterparts.
These results could be explained by the phenomenon of genetic
complementation between two distinct cystinuria loci.
To further explore the hypothesis of distinct genetic loci, we
studied 13 cystinuria patients in Quebec by phenotypic classifica-
tion and by mutational analysis of the D2H gene. Our finding of
D2H mutations only in patients with the Type I phenotype
supports the theory of multiple genetic causes of cystinuria.
Furthermore, our identification of four novel mutations in French
Canadians emphasizes the geographic/ethnic diversity of abnor-
malities of the D2H gene.
Methods
Patients
Thirteen unrelated patients (3 males, 10 females), twelve of
whom were identified by the Quebec Network of Genetic Medi-
cine newborn urinary screening program, were classified between
the ages of one to three years into cystinuria subtypes based on
urinary cystine excretion of obligate heterozygous parents, as
previously described [10]. All probands consistently excreted more
than 1000 j.mol cystine/g. creatinine and excessive amounts of the
dibasic amino acids in the absence of glucosuria, proteinuria or
other signs of renal Fanconi syndrome. Serum amino acid profiles,
urinalysis and renal ultrasonography at the time of diagnosis were
normal. Five probands were classified as I/I homozygotes, seven as
I/Ill genetic compounds and one as a Il/N heterozygote. Two of
the 13 patients (Type I/I homozygotes) subsequently formed
cystine stones in the first decade of life. DNA was extracted from
blood samples obtained with informed consent at the time of
follow-up visits to the Montreal Children's Hospital Renal Ge-
netics Clinic.
Mutation detection
DNA was isolated from blood as previously described [11].
DNAs were first analyzed by Southern blotting to detect large
genomic rearrangements, followed by SSCP analysis (see below).
For Southern analysis, 5 g DNA was digested with the appro-
priate restriction enzyme and the digests were electrophoresed on
0.8% agarose gels. The gels were transferred onto a Nytran Plus
(Schleicher & Schuell) membrane by Southern blotting, and
prehybridization, hybridization and washes were performed ac-
cording to the manufacturer's protocols. The probe was the
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Table 1. Primers for amplification and strategy for mutation detection
Fragment
size
Primers Location bp Mutations Detection
5'-AGACTCCATCGAGATGAGTATG-3'
5'-GGATGCCCCTGGTGCTGTG-3'
(S)
(A)
exonic, bp 24-45
exonic, bp 136-154
131 G38G BsoFI
5'-CAGCTTTAAATATAAAAACTGTITGG-3'
5'-CTCTCAAACCTCATCCCCTC-3'
(S)
(A)
exonic, bp 458-483
intronic, bp 610 + 25 to
bp 610 + 44
197 — —
5'-GTTGTGATAATAACGTAGTFAATG-3'
5'-CTGATGACATYflTCAGAAAAGGC-3'
(S)
(A)
intronic, bp 892-54 to bp
892-3 1
intronic, bp 1011 + 31 to
bp 1011 + 53
227 974delGA heteroduplex analysis
5'-GTCAACGTGATGAACATGCTFC-3'
5'-TGAATACTTGGTTITATAGCTGTG-3'
5'-TTFCAGAAAACTGTGTATACAGC-3'
(S)
(A)
(S)
exonic, bp 1384-1405
intronic, bp 1500 + 29 to
bp 1500 + 52
intronic, bp 1333-51 to
bp 1333-29
169 1500 + 1 G —*T
E483X
—
Mse I (1500 + 1 G — T)
Mbo II . (E483X)
—
5CGGGCCTFCCCGCTAAChAT3
5'-TCCCY]TGTCCAGAAAAATGCC-3'
(S)
(A)
exonic, bp 1835-1853
exonic, bp 1909-1929
95 1618M NIa III
Abbreviations are: (S), sense; (A), antisense. Symbols are: , creation of a natural restriction site; S!,, obliteration of a natural restriction site.
a This intronic primer could be used in conjunction with the antisense intronic primer for amplification of the exon containing bp 1333-1500 to yield
a fragment of 271 bp
h This primer contains a mismatch (T — C) in the indicated location for the creation of an artificial restriction site, NIalli
full-length cDNA for D2H [3], radiolabeled with the Multiprime
oligolabeling kit (Amersham).
For detection of single base substitutions and small insertions!
deletions, PCR of genomic DNA was performed as previously
described [12]. The primers for PCR amplification were derived
from the published cDNA sequence [3, 9]. When the PCR
fragment was larger than the expected size based on coding
sequence alone, it was subcloned and sequenced to obtain intronic
sequence data. Five splice junctions were identified in this man-
ner. The location of the introns and the sequences of the intronic
primers are given in Table 1.
All PCR fragments were run on 9% polyacrylamide gels for the
detection of heteroduplexes [13] to identify small insertions or
deletions. For single base pair substitutions, the PCR fragments
were analyzed by the single strand conformation polymorphism
(SSCP) method, as previously reported [12]. SSCP analysis was
performed with the Phastgel system (Pharmacia), a nonisotopic
rapid SSCP protocol, or with 35S-labeled PCR products run on
6% acrylamide: 10% glycerol gels at room temperature (6 w,
overnight). When abnormal migration was observed on SSCP
gels, the PCR fragments were sequenced directly to identify the
mutation [12]. If the mutation created or obliterated a restriction
site, the sequence change was confirmed by restriction analysis of
a new PCR fragment. Alternatively, a restriction site was artifi-
cially created by introducing a mismatch in the PCR primer [14].
The primer sequences, sizes of PCR fragments, and strategies
for mutation detection are shown in Table 1.
Results
The regions examined by SSCP encompassed approximately
50% of the coding sequences. These regions included bp 1 to 610,
bp 892-1011, bp 1333-1500 and bp 1751 until the end of the coding
sequence at bp 2060. An intron was identified at bp 610. The two
middle regions (bp 892-1011 and bp 1333-1500) are individual
exons while the latter region (bp 1750-2060) did not contain any
introns. The remainder of the genomic structure of D2H requires
further characterization.
Two different mutations were identified in a French Canadian
proband with the I/I phenotype. Figure 1A depicts a Southern blot
of PvuII-digested DNA from proband 817 and his family. A band
of approximately 4.4 kb is seen in the proband, his father and one
of his brothers (lanes 1, 3 and 6, respectively). This band was not
present in the mother or two other sibs (lanes 2, 4, 5). A Southern
blot of Hindlil-digested DNA also revealed an abnormal frag-
ment (approximately 9.5 kb; data not shown), suggesting that a
genomic rearrangement, such as a large deletion, was present in
the paternal D2H gene of this proband. The extra bands were not
seen in Southern blots of control individuals (data not shown).
The second mutation in this family was a S'splice site mutation
in the first nucleotide of the GT consensus dinucleotide in the
intron following bp 1500 (1500+1, G —s T). Since this substitution
created a MseI restriction site, restriction digestion of the PCR
fragment was used to confirm the sequence change in the proband
and his family (Fig. 1B). The mother and one brother (lanes 2 and
4) are carriers of the splice mutation. A second French Canadian
proband (proband 885) has this mutation on one chromosome;
this proband also has the I/I phenotype.
Proband 817 is missing the 168 bp fragment (Fig. 1B) that
represents the allele without the splice mutation. This observation
suggests that the mutation identified by Southern blotting is likely
to be a deletion that encompasses this region of the gene.
In two other unrelated Type I/I probands, we identified a 2 bp
deletion, following bp 974, in the heterozygous state. This muta-
tion was detected by the presence of a heteroduplex and con-
firmed by sequence analysis (Fig. 2A). Since the mutation is within
a
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IóEI
4 5 6 Mol.wt.
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B Family of proband 817IiI LóL
Fig. 1. Mutation analysis in proband 817 and hisC 1 4 5 6 family. A. Southern blot of 5 g of PvuII-
(bp) digested DNA, hybridized with the full-length
cDNA. Lanes 1 to 6 indicate the proband, his
mother, father, and 3 sibs, respectively. B.
Polyacrylamide gel showing the restriction
digestion pattern with MseI for the 1500+1 G
— T mutation. The normal PCR fragment
— 168 168 bp. The mutation creates a MseI restriction
site which is digested into 113 and 55 bp
fragments; the latter fragment is not shown.
— 113 Lanes numbered 1 to 6 indicate the proband,
his mother, father and 3 sibs, respectively. The
first lane, C, is a control. The last lane, 885, is
an unrelated proband with this mutation.
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A
Normal
GA T C
Proband 782
Mutant
GA T C
B Proband 818
cc
cc C C (bp)
(4
11111* Ill/N 1*/N
(1720) (199) (30)
a repeating sequence (GAGAGA), it is impossible to determine
which of the GA dinucleotides has been deleted.
In another Type I/I French Canadian proband, we found a
substitution at bp 1447 (G to T), resulting in a nonsense (E483X)
mutation. This mutation, which obliterates a MboII restriction site
(Fig. 2B), was found on one allele of the patient.
The most common mutation identified thus far in the D2H
gene, the M467T substitution, was first described in Spanish
patients [6]. We identified this mutation in a heterozygous state in
a Type 1/111 genetic compound, proband 947, who excretes cystine
at levels of 1720 p.mol/g creatinine. Analysis of family members
(Fig. 3) by phenotype and genotype indicated that the mutation
was carried by the mother (cystine excretion, 53 mol/g creati-
nine) and by the brother (cystine excretion, 30 j.tmol/g creatinine),
Fig. 2. Mutation analysis in probands 782 and 818.
A. Sequence gel indicating the 2 bp (GA) deletion in
proband 782. The PCR fragments were subcloned
before sequencing. B. Polyaciylamide gel showing the
restriction digestion pattern with MboII for the E483X
mutation in proband 818. The normal PCR fragment
of 168 bp contains a MboII restriction site which
cleaves the fragment into 96 and 72 bp fragments; the
latter fragment is not shown. In patient 818, the
mutation obliterates the MboIl site.
both of whom are predicted to be Type I carriers. The mother is
of Ukrainian/French origin. None of the French Canadian pro-
bands carried this mutation.
The sister of proband 947 was negative for the maternal M467T
mutation. Her increased cystine excretion (199 mol/g creatinine)
must be due to her Type III carrier state, inherited from the father
(cystine excretion = 235 jtmol/g creatinine).
Two previously-identified polymorphisms in codons 38 and 618
(114C—A and 1854A—G) were also identified in French Cana-
dian probands and controls. The 1 14C—A change, originally
identified in one American proband [8], is quite common in the
Spanish/Italian populations [7] as well as in French Canadians,
with allele frequencies of 35% (9 of 26) in our patients and 24%
(16 of 66) in controls. The 1854 A—*G polymorphism is present in
approximately 30% of patient or control alleles in the Spanish/
Italian study [7] and in similar percentages of alleles in French
Canadian patients (35%, 9 of 26) and controls (33%, 22 of 66).
The 2 bp deletion, identified in two of our patients, was present on
two different haplotypes: one haplotype that does not contain
either of these polymorphisms and one haplotype that contains
both. The 1500+1 G — T splice mutation, also present in two
different probands, occurs on the same haplotype in both patients,
indicating that this mutation may have spread from the same
ancestral allele. The M467T mutation was present on the haplotype
without the two polymorphisms; the haplotype linked to this
mutation in the Mediterranean population has not been reported.
Figure 4 depicts the mutations identified thus far in the D2H
gene [6—8, this study. Although there is some overlap in the
polymorphisms (G38G and 1618 M), there is virtually no overlap in
the mutations that are thought to be disease-causing. The single
overlap (M467T in the Spanish and in 1 patient in our study)
could be due to the same ancestral chromosome since our patient
was of mixed European origin.
G— GA AG G
-K >TI
C
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C'
Family of proband 947
— 168
— 96
(235)111/N LI— 1*/N (53)
Fig. 3. Cystinuria subtypes and urinaiy cysrine excretion in proband 947 and
her family. The values in parentheses indicate the urinary cystine values in
mol/g creatinine. Symbol (*) indicates the presence of the M467T
mutation.
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Fig. 4. Composite of D2H mutations identified by Calonge et al[61, Pras et al [8], Gasparini et al [7] and this study. Abbreviation del indicates two large
deletions; the endpoints have not been described. The 18 mutations listed here have been proposed to affect D2H function; changes that are thought
to be benign polymorphisms are not included in this illustration. Abscissa = bp.
Discussion
In this study of 13 cystinuria patients from Quebec, five patients
were classified as I/I homozygotes, seven were 1/111 compounds
and one patient was classified as a Il/N heterozygote. We identi-
fied putative deleterious mutations on seven D2H alleles, all of
which were associated with the Type I phenotype. This observa-
tion is similar to that of Gasparini et al [7] who identified
mutations only in their Type I patients. Linkage analyses also
suggest that the D2H gene is linked to Type I but not to Type III
cystinuria [15]. Whether all Type I patients have mutations in the
D2H gene remains to be determined, since the number of families
analyzed in the linkage study was small [15]. These data strongly
suggest that the D2H gene is the cause of Type I cystinuria, while
other as yet unidentified genes will prove to be responsible for
other subtypes. Candidate genes include cystine transporters
expressed in other segments of the nephron or polypeptide
subunits that could associate with D2H to form a transporter
complex, as previously suggested [7, 9].
The four novel mutations identified in this study (a large
deletion, a splice site mutation, a nonsense mutation and a 2 bp
deletion) are likely to inactivate the D2H gene, in contrast to
missense mutations which require expression analysis to confirm
their deleterious effects. Thus far, only one of the many missense
mutations in the D2H gene has been expressed; it is associated
with a loss of 80% of activity [6]. Mutations which completely
inactivate the gene might be associated with higher levels of
cystine excretion than mutations which retain partial activity. The
levels of cystine excretion in our patients with the above four
mutations ranged from 3650 to 7940 j.tmollg creatinine; two of
these patients formed stones at the age of 7. These values are
higher than the cystine excretion values previously reported for
the M467T homozygotes (range 828 to 1439 .tmol/g) [6], who may
retain some activity from the gene product, if one can extrapolate
from the in vitro data to the in vivo situation. However, these types
of genotype:phenotype correlations have to be made with caution,
since our values for urinary cystine are primarily from the
newborn period while the patients in the Spanish study were
ascertained at a much later age [61. In addition, we have not
identified both mutations in all our probands; the second uniden-
tified allele may not be completely inactivated. Nonetheless, the
availability of newborn screening in Quebec allows us to obtain
excretion values at a common timepoint for all our patients, thus
facilitating phenotypic classification and genotype:phenotype cor-
relations.
The population specificity of D2H mutations is quite striking,
with little overlap in the mutations identified in three different
populations. Although a founder effect has contributed to in-
creased frequency of specific mutations in several other genes in
French Canadians, no deleterious D2H mutation was identified in
more than two patients. Our probands, however, are from a large
urban center, Montreal, which has a greater admixture of popu-
lations than the northeastern Sagenuay—Lac St. Jean community,
where founder events have been observed [16, 17].
The identification of polymorphisms in the D2H gene is useful
for population genetic analyses. The 114C—*A and 1854A—G
polymorphisms are frequent in both the Mediterranean and
French Canadian populations while the disease-causing mutations
are specific to the individual groups (our only family with the
previously described M467T mutation was of mixed European
lineage). Thus the benign polymorphic changes appear to be of
earlier origin than the deleterious mutations, which have not yet
had adequate time for admixture.
The analysis of haplotypes allows us to predict that the 2 bp
deletion was a recurrent mutation, rather than inherited from a
common ancester, since it was associated with two different
haplotypes. In contrast, the splice site mutation in two patients
was associated with the same haplotype. Our patient with the
M467T mutation carried this substitution on a common haplo-
type, one which did not contain the 114C—A or the 1854A—*G
polymorphisms. Description of the haplotype associated with this
mutation in the Spanish population would have been useful in
determining whether our patient and the Spanish patients shared
a common founder.
Since cystine excretion in one individual may vary according to
age, salt intake, time of day, etc., a single measurement of urinary
cystine may be sub-optional as a predictor for life-long risk of
nephrolithiasis. The identification of D2H mutations in cystinuria
patients may complement the measurement of cystine excretion in
974delGA
P1 28R R270X
E483X (Horsford et al)
M467T 1500+1 G—T
R181Q
(Prasetal, 1994)
(Calogne et al, 1994)
(Gasparini et al, 1995)
F648S
1749delA T652R
Y582H P615T L678P
UAG
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the selection of patients with high risk of nephrolithiasis for
anticipatory intervention.
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